Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
E Blass, PA Ott - Nature reviews Clinical oncology, 2021 - nature.com
Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …
cancers with the development and regulatory approval of various immune-checkpoint …
Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
C Riou, R Keeton, T Moyo-Gwete… - Science translational …, 2021 - science.org
SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have
emerged. T cell responses play a role in protection from reinfection and severe disease, but …
emerged. T cell responses play a role in protection from reinfection and severe disease, but …
Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data
B Reynisson, C Barra, S Kaabinejadian… - Journal of proteome …, 2020 - ACS Publications
Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …
Improved methods for predicting peptide binding affinity to MHC class II molecules
Major histocompatibility complex class II (MHC‐II) molecules are expressed on the surface
of professional antigen‐presenting cells where they display peptides to T helper cells, which …
of professional antigen‐presenting cells where they display peptides to T helper cells, which …
Alternative tumour-specific antigens
The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …
accelerated within the past decade. The most commonly studied class of TSAs are those …
Predicting HLA class II antigen presentation through integrated deep learning
Accurate prediction of antigen presentation by human leukocyte antigen (HLA) class II
molecules would be valuable for vaccine development and cancer immunotherapies …
molecules would be valuable for vaccine development and cancer immunotherapies …
IEDB-AR: immune epitope database—analysis resource in 2019
Abstract The Immune Epitope Database Analysis Resource (IEDB-AR, http://tools. iedb. org/)
is a companion website to the IEDB that provides computational tools focused on the …
is a companion website to the IEDB that provides computational tools focused on the …
Neoantigens: promising targets for cancer therapy
Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes
J Racle, J Michaux, GA Rockinger, M Arnaud… - Nature …, 2019 - nature.com
Predictions of epitopes presented by class II human leukocyte antigen molecules (HLA-II)
have limited accuracy, restricting vaccine and therapy design. Here we combined unbiased …
have limited accuracy, restricting vaccine and therapy design. Here we combined unbiased …